Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory for Molecular Medicine, |
RCV001195632 | SCV001366031 | uncertain significance | not specified | 2019-11-13 | criteria provided, single submitter | clinical testing | The c.44-12_44-8dup (NM_003990.3) variant in PAX2 has not been previously reported in individuals with papillorenal syndrome and was absent from large population studies. In most PAX2 transcripts, this duplication is located in the 3' splice region of intron 1. While computational tools do not predict a splicing impact, this information is not predictive enough to rule out pathogenicity. It should also be noted this variant falls within the coding region of at least one PAX2 transcript (ENST00000554172.1: c.44_48dup (p.Ser17ValfsX10)) that is expressed in kidney tissue (GTEx, https://www.gtexportal.org/home/). On the ENST00000554172.1 transcript, the duplication is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 17 and leads to a premature termination codon 10 amino acids downstream. While loss of function of the PAX2 gene is an established disease mechanism for autosomal dominant papillorenal syndrome, at this time there is insufficient evidence to determine if ENST00000554172.1 is a biologically relevant transcript. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2. |
| Labcorp Genetics |
RCV002560205 | SCV002991283 | likely benign | Renal coloboma syndrome; Focal segmental glomerulosclerosis 7 | 2024-02-24 | criteria provided, single submitter | clinical testing |